Carla Murer

Initial results from a phase I, open-label, dose escalation study of the oral BRAF inhibitor LGX818 in patients with BRAF V600 mutant advanced or metastatic melanoma.

Reinhard Dummer, Caroline Robert, Marta Nyakas et al. · Journal of Clinical Oncology · 2013 · 45 citations

Immunology, Pathology, Immunotherapeutics +18

Gender differences in psoriasis: a Swiss online psoriasis survey

Carla Murer, David Sgier, Sofia K. Mettler et al. · Archives of Dermatological Research · 2020 · 32 citations

Sexual Health, Sexual And Reproductive Health, Medicine +7

Efficacy of Omalizumab in Mastocytosis: Allusive Indication Obtained from a Prospective, Double-Blind, Multicenter Study (XOLMA Study)

Meike Distler, Julia‐Tatjana Maul, Urs C. Steiner et al. · Dermatology · 2020 · 27 citations · Full text

Mucocutaneous Ulcerations and Pancytopenia due to Methotrexate Overdose

Katharina Knoll, Florian Anzengruber, Antonio Cozzio et al. · Case Reports in Dermatology · 2016 · 22 citations · Full text

Mtx Therapy, Immunotherapy, Mtx Toxicity +14

Clinical observation of panniculitis in two patients with BRAF-mutated metastatic melanoma treated with a combination of a BRAF inhibitor and a MEK inhibitor

N. Galliker, Carla Murer, Jivko Kamarashev et al. · European Journal of Dermatology · 2015 · 20 citations · Full text